Close Menu

NEW YORK (GenomeWeb) – Promega said today that it has non-exclusively licensed the Broad Institute's CRISPR-Cas9 intellectual property.

Under the terms of the agreement, Promega will combine the Broad's CRISPR-Cas9 technology with its own products for knock-in of genetic reporters into the genomes of any cell or cell line. The firm is aiming to develop and sell gene editing tools and reagents for interrogating endogenous biology at physiologically relevant expression levels.

Financial terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

The Wall Street Journal examines billing codes used by uBiome.

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.